Table 1 Patient characteristics

From: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

Number of patients 42
Gender
 Male 19 (45%)
 Female 23 (55%)
Age (years)
 Median (range) 59 (43–73)
ECOG performance status
 0 12 (29%)
 1 30 (71%)
Tumour location
 Head 21 (50%)
 Body–tail 21 (50%)
CEA (ng ml1)
 Median (range) 11 (1.0–62.7)
CA19-9 (U ml1)
 Median (range) 2775 (1–15 620)
  1. ECOG=Eastern Cooperative Oncology Group; CEA=carcinoembryonic antigen; CA19-9=carbohydrate antigen 19-9.